Genzyme has discontinued development of the potential follow-on to its drug Renvela (sevelamer carbonate), as the advanced phosphate binder (APB) did not show a significant improvement in phosphate lowering compared with Renvela in a Phase II/III trial in adult haemodialysis patients with hyperphosphataemia.
Genzyme has discontinued development of the potential follow-on to its drug Renvela (sevelamer carbonate), as the advanced phosphate binder (APB) did not show a significant improvement in phosphate lowering compared with Renvela in a Phase II/III trial in adult haemodialysis patients with hyperphosphataemia.
Genzyme was seeking to develop a product with higher potency that would more effectively bind phosphate.
Create an account to read this article
Already a subscriber?
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Swiss major confident that new oncology drugs will fill revenue gap.
Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
